Boston, MA 06/05/2013 (wallstreetpr) – The share prices of Rosetta Genomic Ltd. USA (NASDAQ:ROSG) had surged by 8.22 percent to close at $3.95 per share for the end of last trading session on Tuesday. The shares of the company had been trading in the range of $3.73 to $4.22 per share during the day. The shares of Rosetta Genomic Ltd. USA (NASDAQ:ROSG) had recorded 52 week low price level of $3.09 per share and 52 week high price level of $17.35 per share.
Rosetta Genomic Ltd. USA (NASDAQ:ROSG) is engaged in the development and commercialization of diagnostic tests, the technology of which is based on discovered group of genes called micro RNAs. The development, validation and commercialization of the diagnostic tests developed by the company using its micro RNA technology are made possible through the laboratory in Philadelpia, which had been certified under clinical laboratory improvement amendment (CLIA).
Rosetta Genomic Ltd. USA (NASDAQ:ROSG) had until now launched five diagnostic tests developed based on its micro RNA technology namely miRview mets, miRview mets2, miRview lung, miRview meso and miRview squamous. The shares of the diagnostic test developer had recently hit new lows and have presently surged from the bottom to trade at higher levels.
Rosetta Genomic Ltd. USA (NASDAQ:ROSG) had witnessed heavy trading volume on Tuesday with nearly 1.63 million shares being exchanged hands, while the average trading volume of the company is at 310,831 shares per day. The company presently holds 701,162 shares outstanding in the market with 69 percent institutional ownership.
